Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.98 |
| ▸ | MAP2K2 | P36507 | 19/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | BRAF | P15056 | 1/20 | 0.61 |
| ▸ | DRD1 | P21728 | 1/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | ACTR3 | P61158 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30221109 | 0.99 | MAP2K1 (1.00) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL188571 | 0.99 | MAP2K1 (1.00) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL29413479 | 0.97 | MAP2K1 (0.96) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL1488289 | 0.97 | MAP2K1 (0.96) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL1488008 | 0.92 | MAP2K1 (0.82) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL30220982 | 0.92 | MAP2K1 (0.82) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL29413406 | 0.91 | MAP2K2 (0.85) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL1488083 | 0.91 | MAP2K2 (0.85) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL1488065 | 0.91 | MAP2K2 (0.85) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL1488072 | 0.91 | MAP2K1 (1.00) | MAP2K1MAP2K2CHRM2CHRM1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2019-05-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | BRAF, NRAS, MAP3K20 | MAP2K1 52/4885MAP2K2 49/4885CHRM2 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.